Join our community of smart investors

Oxford BioMedica signs second contract

The gene and cell therapy specialist enjoyed another 9 per cent share price leap on the day of the announcement
February 20, 2018

Oxford BioMedica (OXB) has signed a collaboration and licence agreement with haemophilia specialist Bioverativ. The agreement allows the US-based company – which was recently bought by French pharma giant Sanofi – access to OXB’s LentiVector platform, which will be used to help develop a novel treatment for haemophilia.

IC TIP: Hold at 12p

OXB will receive $5m (£3.6m) upfront and various milestone payments, potentially worth $100m.